Britain and America have agreed to a key commercial pact that will keep zero duties on UK drug shipments being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to boost spending on pharmaceuticals through the National Health Service (NHS). This pledge secures that import taxes on these key exports will stay at zero for a timeframe of the next three years.
This agreement comes after recent statements to dramatically increase import taxes on patented pharmaceutical products, with figures floated as high as double the cost.
"This agreement with the UK bolsters the global environment for innovative medicines and establishes long-overdue fairness to transatlantic drug exports," an announcement declared.
Economic Significance
Drugs constitute one of the Britain's largest exports to the United States, which is clearly the biggest destination for large UK drugmakers.
Export figures reveal that in the one-year period leading up to September, the UK shipped pharmaceutical products worth £11.1bn to the US. This figure represented nearly one-fifth of British export trade in that period.
"This deal secures work, boosts capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a minister remarked.
Specific NHS Changes
The agreement involves several specific pledges from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise overall health service expenditure on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Last year, rebates topped 20%.
Broader Context
This agreement takes place against a protracted row between the sector and the ministers over drug pricing and approval rates.
The disagreement were intensified by arguments that US patients were charged a premium for the identical medicines than patients in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
One official acknowledged that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
